

Dear Editor, World Journal of Hepatology

We appreciated your great efforts during evaluation of our research which added too much to our knowledge; we will do our best to respond to the reviewers comments properly. All the changes were made in the text by word track changes.

Much Obliged

Reviewers' comment

This article found out that treating HCV with DAAs therapy was effective in improving the virus-related extrahepatic cutaneous manifestations. This study was an observational prospective hospital-based study which was important to lead to the conclusion. This was the first study that assesses and follow up extrahepatic cutaneous manifestations using a dermatoscope. The conclusions appropriately summarize the data that this study provided. The limitations of the study was that the number of enrolled patients were too small. This study could be better if it enrolled more patients.

Response to Reviewers' comment

Thanks sir for your positive feedback, and we really appreciate your valuable and important comments.

We totally agree that number of enrolled patients were small, as we were able to recruit 30 subjects after the screening of 1039 HCV patients over seven months period. This relatively small number of patients in our study could be explained by the fact that most cases with HCV related dermatological manifestations were discovered and treated at earlier stages of HCV treatment project in Egypt. Being a pilot study with the first time to use dermoscope in

evaluating the response of extrahepatic cutaneous manifestations to HCV treatment with DAAs, further studies with a larger number of patients and more diverse dermatological lesions are recommended to confirm our results.

We added a separate paragraph to the discussion section to handle (the limitations to our study), and we explained the previous situation, and recommended to have further studies to this pilot work to confirm the results.

Once again, thanks for the valuable comments and support.

Best regards

Authors.